Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Poliomyelitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape. Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 1, 2 and 1 molecules, respectively. Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Poliomyelitis - Overview Poliomyelitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Poliomyelitis - Therapeutics Assessment Assessment by Target Assessment by Route of Administration Assessment by Molecule Type Poliomyelitis - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd Bharat Biotech International Ltd Biological E Ltd Biological Mimetics Inc Boryung Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd GlaxoSmithKline Plc Grifols SA Johnson & Johnson Kaketsuken KK LG Chem, Ltd. Nanolek Panacea Biotec Ltd Sanofi Sanofi Pasteur SA Sentinext Therapeutics Sdn Bhd Shantha Biotechnics Pvt Ltd Taiga Biotechnologies Inc Takeda Pharmaceutical Company Ltd Poliomyelitis - Drug Profiles (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress BK-1310 - Drug Profile Product Description Mechanism Of Action R&D Progress BVN-002 - Drug Profile Product Description Mechanism Of Action R&D Progress DTaP-IPV-HB-PRPT - Drug Profile Product Description Mechanism Of Action R&D Progress immune globulin (human) - Drug Profile Product Description Mechanism Of Action R&D Progress ImmunoRx - Drug Profile Product Description Mechanism Of Action R&D Progress IPVGVI-3000 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-2348 - Drug Profile Product Description Mechanism Of Action R&D Progress KD-370 - Drug Profile Product Description Mechanism Of Action R&D Progress LBVC - Drug Profile Product Description Mechanism Of Action R&D Progress LBVD - Drug Profile Product Description Mechanism Of Action R&D Progress polio (virus like particle, bivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio [strain Sabin] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress polio vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress poliomyelitis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress poliomyelitis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress poliomyelitis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress TAK-195 - Drug Profile Product Description Mechanism Of Action R&D Progress VN-0105 - Drug Profile Product Description Mechanism Of Action R&D Progress Poliomyelitis - Dormant Projects Poliomyelitis - Discontinued Products Poliomyelitis - Product Development Milestones Featured News & Press Releases Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate May 11, 2011: Sanofi Pasteur Launches Pentaxim In China Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Poliomyelitis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017 Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H1 2017 Poliomyelitis - Pipeline by Biological E Ltd, H1 2017 Poliomyelitis - Pipeline by Biological Mimetics Inc, H1 2017 Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017 Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H1 2017 Poliomyelitis - Pipeline by Grifols SA, H1 2017 Poliomyelitis - Pipeline by Johnson & Johnson, H1 2017 Poliomyelitis - Pipeline by Kaketsuken KK, H1 2017 Poliomyelitis - Pipeline by LG Chem, Ltd., H1 2017 Poliomyelitis - Pipeline by Nanolek, H1 2017 Poliomyelitis - Pipeline by Panacea Biotec Ltd, H1 2017 Poliomyelitis - Pipeline by Sanofi, H1 2017 Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1 2017 Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2017 Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017 Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H1 2017 Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Poliomyelitis - Dormant Projects, H1 2017 Poliomyelitis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
